메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

국제 암 기관들, 베트남 여성 암 환자의 치료 수요 충족 위해 협력

미국종합암네트워크, 베트남 국립암병원과 협력해 유방암 및 난소암 치료 위한 지역 맞춤형 권고안 마련 하노이, 베트남, 2026년 2월 2일 -- 미국의 주요 암 치료 기관 연합체인 미국 종합암네트워크(National Comprehensive Cancer Network®, NCCN®)가 베트남 국립암병원(Vietnam National Cancer Hospital, K Hospital)과 협력해 베트남 전역의 암 환자 치료 성과를 개선하기 위한 노력에서 중요한 이정표를 세우는 중이다. 양 기관은 유방암과 난소암을 대상으로 한 베트남 전용 NCCN 종양학 임상실무지침(NCCN Clinical Practice Guidelines in Oncology®, NCCN Guidelines®)을 공식 발표했으며 이는 베트남 여성에서 발생률이 높은 암종에 대응하고, 전반적인 진료의 질을 향상하며 역내에서 베트남의 역할을 강화하겠다는 의지를 보여준다. 지역별 실무 관행, 규제 상태, 의료 기술 수준을 반영해 맞춤화된 NCCN 지침 해외 번안®(International Adaptations of the
- 김갑성 기자
- 2026-02-02 08:08
세인트 데이비드 메디컬 센터 산하 텍사스 심장 부정맥 연구소, 미국 최초로 FDA 승인 신형 제세동 리드 이식 성공

[ 메디채널 김갑성 기자 ] 세계에서 가장 작은 카테터 전달 방식의 제세동 리드를 가진 신기술 오스틴, 텍사스, 2026년 2월 2일 -- 세인트 데이비드 메디컬 센터(St. David's Medical Center) 산하 텍사스 심장 부정맥 연구소(Texas Cardiac Arrhythmia Institute, TCAI)의 심장 전기생리 전문의들이 최근 미 식품의약국(FDA) 승인을 받은 신형 제세동 리드를 미국 최초로 이식하는 데 성공했다. 이 리드는 이식형 제세동기(ICD) 또는 심장 재동기화 치료기(CRT-D)를 심장에 연결해 비정상적인 리듬을 교정하는 특수 절연 와이어다. 이 제세동 리드는 [ 메디채널 김갑성 기자 ] 세계에서 가장 작은 카테터 전달 방식의 제세동 리드로, 우심실에 정밀한 전달과 위치 고정이 가능하다. 첫 번째 시술은 1월 7일 텍사스 심장 부정맥 연구소의 임상 심장 전기생리 전문의인 로버트 캔비(Robert Canby) 의학박사와 아민 알아마드(Amin Al-Ahmad) 의학박사가 집도했다. 캔비 박사는 FDA 승인으로 이어진 임상시험에도 참여했다. 텍사스 심장 부정맥 연구소의 심장 전
- 김갑성 기자
- 2026-02-02 08:08
Aphranel Launches "The Poetics of Time" Brand Strategy at IMCAS Paris, Redefining Long-Term Value in Medical Aesthetics

PARIS, Feb. 1, 2026 -- At the 2026 International Master Course on Aging Science (IMCAS) World Congress in Paris, Aphranel, a China-origin regenerative medical aesthetics brand specializing in CaHA injectables, under the company SHANGHAI MOYANG BIOTECHNOLOGY, unveiled its global brand strategy, "The Poetics of Time." The launch marked Aphranel's introduction of its long-term aesthetic philosophy to an international audience. Held in a historic Parisian cinema, the event reflected Aphranel's intention to reframe how medical aesthetics considers time, shifting focus fro
- 김갑성 기자
- 2026-02-01 14:22
Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"

SHANGHAI, Jan. 31, 2026 -- Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental transformation. In 2015, as regulatory reform ignited local innovation, Lang Guojun, after earning his PhD from Zhejiang University and gaining several years of experience in pharmaceutical companies, foresightedly focused on the core upstream segment of the industry value chain and founded Sanyou Biopharmaceuticals (hereinafter referred to as "Sanyou Bio").&
- 김갑성 기자
- 2026-01-31 16:15
NYSE Content Advisory: Pre-Market Update + Cast of HBO's 'Industry' Rang Thursday's Closing Bell

NEW YORK, Jan. 30, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Cast of HBO's ‘Industry’ Rang Thursday's Closing Bell Ashley Mastronardi delivers the pre-market update on January 30th Stocks are trading lower but trimming losses after President Donald Trump named Kevin Warsh as his pick to replace Fed Chair Jerome Powell, while markets also react to tech earnings
- 황정호 기자
- 2026-01-30 22:02
Global Appeal 2026 Highlights Education as the Key to Ending Leprosy Stigma and Discrimination

[ 메디채널 김갑성 기자 ] --Launch Ceremony in Brussels Preceded by Royal Audience-- TOKYO, Jan. 30, 2026 -- The 2026 Global Appeal to End Stigma and Discrimination Against Persons Affected by Leprosy was launched in Brussels, Belgium on January 29 at an event co-hosted by Education International and the Sasakawa Leprosy (Hansen's Disease) Initiative, in partnership with the Damien Foundation. Now in its 21st year, the Global Appeal is an annual call to action aiming to mobilize different sectors of society to sign a collective pledge to eliminate the social barriers surrounding leprosy
- 김갑성 기자
- 2026-01-30 21:11
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

[ 메디채널 김갑성 기자 ] Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic pr
- 김갑성 기자
- 2026-01-30 21:00
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes

HANGZHOU, China, Jan. 30, 2026 -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist. The number of diabetes patients in China has been increasing steadily over the past decades, reaching approximately 148 million by 202
- 김갑성 기자
- 2026-01-30 19:54
Virtus Medical Group and Hong Kong Healthcare Foundation jointly present the inaugural 'Hong Kong Nordic Walkathon 2026', fully supported by China Construction Bank (Asia)

[ 메디채널 김갑성 기자 ] Public registration for the event is now open. A transformative city-wide health initiative bringing the proven benefits of Nordic Walking to 5,000 participants at Tamar Park HONG KONG, Jan. 30, 2026 -- Virtus Medical Group ("Virtus") and the Hong Kong Healthcare Foundation jointly announced today that they will co-host the inaugural 'Hong Kong Nordic Walkathon 2026', fully supported by China Construction Bank (Asia) ("CCB (Asia)"). This landmark health event is scheduled to take place on 1 March 2026, Sunday, at Tamar Park, Admiralt
- 김갑성 기자
- 2026-01-30 15:29
World Gym Corporation Presents at 2026 ICR Conference

Company Management Explores Public Listing in the U.S. and Highlights Launch of New Biomarker Tech Integration TAIPEI, Jan. 30, 2026 -- World Gym Corporation (2762.TW) ("World Gym " or the "Company"), the owner of the iconic World Gym brand with over 280 locations worldwide, recently presented at the 28th Annual ICR Conference, one of the largest growth company investment conferences of the year with over 3,000 attendees. During the conference, the company held many investor and banker meetings to raise awareness of the business and explore a potential cap
- 노기식 기자
- 2026-01-30 15:07

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-02-02_MON

2026-02-01_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 02월 02일 09시 30분